Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

BeiGene: Clinical Trials & FDA Approval Profile

BeiGene (San Mateo, CA / Basel, CH) sponsors 87 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 36 active protocols (17 recruiting now), 43 completed protocols, and 6 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)9.2%
Median Closed Enrollment vs National (145 pts)125 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for BeiGene
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)87
Active Pipeline (Recruiting Now)36 (17)
Completed vs Stopped Early43 / 8 (9.2%)
Median Closed Actual Enrollment125 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals6 (6 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With BeiGene
Hospital Research SiteLocationShared Protocols
Henan Cancer HospitalZhengzhou, Henan44
Harbin Medical University Cancer HospitalHarbin, Heilongjiang39
Beijing Cancer HospitalBeijing, Beijing Municipality37

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by BeiGene
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT03736889Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid TumorsPhase IIRECRUITING
NCT06973187A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory ChronicPhase IIIRECRUITING
NCT07277231A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With PreviPhase IIIRECRUITING
NCT06943872A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax PPhase IIIRECRUITING
NCT07043400A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With UnPhase IIIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the BeiGene Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI